Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Webside Discussions 2 - Coronavirus & Cancer Treatment Pt 3 Challenges & Future for In Person Care
Webside Discussions Updates - Coronavirus & Cancer Treatment Pt 3 - Challenges and the Future Outlook for In Person Patient Care, Presented July 2020
Image
In part three of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.
GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy discuss cancer and Covid-19 and how the ongoing pandemic is effecting in person patient care.
-
Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
-
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
-
Part 3 - Challenges and the Future Outlook for In Person Patient Care
To join the conversation, visit https://cancergrace.org/forum.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.